Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2015

View Archived Issues

Principia evaluating PRN-1371 in phase I trial for advanced solid tumors

Effector Therapeutics initiates trial of Mnk1/2 inhibitor eFT-508 in patients with solid tumors

FXR agonist EYP-001 shows activity against HBV replication

EMA accepts Helsinn's MAA for anamorelin in cancer-related cachexia

New CD137/HER2 bispecific Anticalin-based protein shows promising antitumoral activity

Fibroblast activation inhibitor preserves cardiac function after heart failure in animal model

Sprint Bioscience collaborates with Gothenburg University on diabetes program

University of Colorado patents HDAC/TTK inhibitors

Takeda and Teva to form Japanese generic pharmaceuticals venture

Peloton Therapeutics disclosed ACSS2 inhibitors

AbbVie announces V1bR ligands

X-Rx reports autotaxin inhibitors

Array BioPharma patents Trk-A inhibitor

Bayer Schering Pharma divulges sGC activators

Novartis discloses TLR7 agonists

FDA issues complete response letter for Opdivo

EC grants marketing authorization for Numient in the treatment of Parkinson's disease

Oncoceutics starts phase I trial of ONC-201 in solid tumors and multiple myeloma

Rottapharm's antibody CRB-0017 prevents joint damage in animal models of osteoarthritis

PCSK9 vaccine reduces cholesterol and triglyceride levels in mice and monkeys

Gene therapy that restores copper metabolism in model of Wilson disease granted E.U. orphan status

Novel biomarkers of lupus nephritis activity identified through urinary proteomics

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...